中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (6): 482-486.doi: 10.19401/j.cnki.1007-3639.2017.06.014

• 论著 • 上一篇    下一篇

OTUB1在90例卵巢黏液性肿瘤中的表达分析

朱 勤,陆铃慧,王懿琴   

  1. 复旦大学附属妇产科医院病理科,上海 200011
  • 出版日期:2017-06-30 发布日期:2017-07-26
  • 通信作者: 王懿琴 E-mail: yiqinwang11@icloud.com
  • 基金资助:
    国家自然科学基金会青年项目(81602269)。

Immunohistochemical analysis of OTUB1 in 90 cases of ovarian mucinous tumors

ZHU Qin, LU Linghui, WANG Yiqin   

  1. Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China
  • Published:2017-06-30 Online:2017-07-26
  • Contact: WANG Yiqin E-mail: yiqinwang11@icloud.com

摘要: 背景与目的:卵巢黏液性肿瘤是卵巢上皮性肿瘤的主要亚型之一,其恶变机制目前尚未明确。泛素化是人体主要的翻译后修饰机制,并与肿瘤密切相关。去泛素化酶可通过逆转泛素化过程从而影响肿瘤的发生、发展。该研究旨在分析编码人体最主要的去泛素化酶的癌基因泛素醛结合物1(OTU deubiquitinase,ubiquitin aldehyde binding 1,OTUB1)在卵巢黏液性肿瘤中的蛋白表达及临床应用。方法:收集2010—2015年复旦大学附属妇产科医院病理科诊断的卵巢良性黏液性囊腺瘤、卵巢交界性黏液性肿瘤及卵巢原发性黏液性癌病例共90例,收集临床病理资料,完成OTUB1的免疫组织化学法表达实验并作统计分析。结果:90例卵巢黏液性肿瘤中,卵巢良性黏液性囊腺瘤有14例,卵巢交界性黏液性肿瘤有17例,卵巢原发性黏液性癌有59例。OTUB1在卵巢原发性黏液性癌的蛋白表达率及阳性程度显著高于卵巢良性黏液性囊腺瘤(P<0.01);OTUB1在卵巢交界性黏液性肿瘤中上皮内癌的阳性率显著高于肠型交界性黏液性肿瘤(P<0.01);随着FIGO分期增高,OTUB1的阳性率及阳性程度增加(P<0.05);OTUB1在输卵管有累及的患者中表达率及阳性程度均高于未累及者(P<0.05);OTUB1在子宫和大网膜累及的患者中阳性率及阳性程度均高于未累及者(P<0.05);OTUB1在有淋巴结转移的患者中表达率及阳性程度均高于无转移者(P<0.05)。结论:OTUB1在卵巢原发性黏液性癌中的蛋白表达水平明显高于卵巢良性黏液性囊腺瘤,并且和FIGO分期及肿瘤侵袭转移性高度相关。在临床病理中可将OTUB1作为卵巢黏液性肿瘤恶变与否的评价指标及肿瘤进展的辅助判别指标。

关键词: 泛素醛结合物1, 卵巢, 黏液性肿瘤

Abstract: Background and purpose: The ovarian mucinous tumor is one of the major subtypes of the ovarian epithelial cancer. Ubiquitination is one of the main post-translational modifications, which has proven to be involved in tumorigenicity. Deubiquitinase is the protein enzyme that could reverse the process of ubiquitination to affect the initiation and progression of malignancies. This study aimed to analyze the expression and clinical application of deubiquitinase OTUB1 (OTU deubiquitinase, ubiquitin aldehyde binding 1) in ovarian primary mucinous tumors. Methods: This study collected 90 cases of ovarian primary mucinous tumors during 2010-2015 in Obstetrics and Gynecology Hospital of Fudan University, and then collected the clinicopathological information and performed the immunochemistry. Results: Fourteen out of 90 cases were ovarian primary mucinous cystadenoma, 17 were borderline mucinous tumor (intestinal type and intraepithelial carcinoma), and 59 were ovarian primary mucinous carcinoma. The expression rate and intensity of OTUB1 were much higher in malignant cases than those in benign ones (P<0.05). The expression rate and intensity of OTUB1 were much higher in cases with mucinous intraepithelial carcinoma than those in cases with intestinal type borderline mucinous tumor (P<0.05). The expression rate and intensity of OTUB1 increased with the advance of FIGO staging (P<0.05). The expression rate and intensity of OTUB1 were much higher in cases with involved fallopian tubes than those in cases without involved fallopian tubes (P<0.05). The expression rate and intensity of OTUB1 were much higher in cases with involved uterus and omentum than those in cases without involvement (P<0.05). The expression rate and intensity of OTUB1 were much higher in cases with lymph node metastasis than those in cases without involvement (P<0.05). Conclusion: There is significant difference in OTUB1 expression between ovarian primary mucinous carcinoma and benign mucinous cystadenoma. It is highly correlated to FIGO staging and invasion and metastasis of tumor. OTUB1 could be used in differential diagnosis and in monitoring the tumor initiation and progression in ovarian mucinous carcinoma.

Key words: OTU deubiquitinase, ubiquitin aldehyde binding 1, Ovary, Mucinous tumors